Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DX6RV3
|
|||
| Drug Name |
IVA337
|
|||
| Synonyms |
Lanifibranor; 927961-18-0; IVA-337; UNII-28Q8AG0PYL; 28Q8AG0PYL; CHEMBL4091374; CPD1537; 4-(1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic acid; 1H-Indole-2-butanoic acid, 1-(6-benzothiazolylsulfonyl)-5-chloro-; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]butanoic acid; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid; Lanifbranor; Libfranor; Lanifbranor [INN]; Lanifibranor(IVA-337); SCHEMBL3528615; AMY16813; EX-A1511; BDBM50244350; s8770; DB14801; SB18746; AC-31451; AK689102; BS-17993; HY-104049; CS-0027586; Q27896056; 1-(6-Benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic Acid; 5-Chloro-1-((6-benzothiazolyl)sulfonyl)-1H-indole-2-butanoic acid; 4-(1-(benzo[d]thiazol-6-ylsulfonyl)-5-chloro-1H-indol-2-yl)butanoic acid; BJB
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-alcoholic steatohepatitis [ICD-11: DB92.1; ICD-10: K75.8; ICD-9: 571.8] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H15ClN2O4S2
|
|||
| Canonical SMILES |
C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2
|
|||
| InChI |
1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)
|
|||
| InChIKey |
OQDQIFQRNZIEEJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 927961-18-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Peroxisome proliferator-activated receptor (PPAR) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03008070) Phase 2b Study in NASH to Assess IVA337 (NATIVE). U.S. National Institutes of Health. | |||
| REF 2 | Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017 Nov;76(11):1931-1940. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.